43,304 Shares in Chemed Corporation $CHE Purchased by Assenagon Asset Management S.A.

Key Points

• Assenagon Asset Management purchased 43,304 Chemed shares worth approximately $21.9 million, giving it a 0.33% stake. Institutional investors collectively own 95.85% of the company.
• Chemed reported quarterly EPS of $6.06, exceeding the $5.60 consensus estimate, while revenue rose 8.8% year over year to $673.25 million. The company issued fiscal 2026 EPS guidance of $25.00–$25.75.
• Chemed increased its quarterly dividend from $0.60 to $0.70 per share, although insiders have sold 9,190 shares worth about $4.83 million over the past 90 days. Analysts maintain a consensus “Hold” rating with a $554.60 target price.

Assenagon Asset Management S.A. bought a new stake in Chemed Corporation (NYSE:CHE - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm bought 43,304 shares of the company's stock, valued at approximately $21,872,000. Assenagon Asset Management S.A. owned about 0.33% of Chemed as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in CHE. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of Chemed during the 2nd quarter worth about $34,000. Versant Capital Management Inc raised its position in shares of Chemed by 7,500.0% during the second quarter. Versant Capital Management Inc now owns 76 shares of the company's stock valued at $35,000 after buying an additional 75 shares during the last quarter. Keating Financial Advisory Services Inc. bought a new stake in shares of Chemed in the second quarter valued at about $36,000. MassMutual Private Wealth & Trust FSB lifted its stake in shares of Chemed by 65.3% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 81 shares of the company's stock valued at $38,000 after buying an additional 32 shares during the period. Finally, Global Retirement Partners LLC bought a new stake in shares of Chemed in the second quarter valued at about $49,000. 95.85% of the stock is owned by institutional investors.

Chemed Price Performance

Shares of CHE stock opened at $512.20 on Monday. The stock's fifty day simple moving average is $517.57 and its 200 day simple moving average is $471.79. Chemed Corporation has a one year low of $365.20 and a one year high of $557.00. The firm has a market cap of $6.69 billion, a price-to-earnings ratio of 25.73, a P/E/G ratio of 2.06 and a beta of 0.51. The company has a debt-to-equity ratio of 0.17, a current ratio of 0.91 and a quick ratio of 0.89.

Chemed (NYSE:CHE - Get Free Report) last released its quarterly earnings data on Tuesday, July 28th. The company reported $6.06 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.60 by $0.46. The firm had revenue of $673.25 million during the quarter, compared to analyst estimates of $665.04 million. Chemed had a return on equity of 31.77% and a net margin of 10.60%. The business's revenue for the quarter was up 8.8% compared to the same quarter last year. During the same period in the prior year, the company posted $4.27 earnings per share. Chemed has set its FY 2026 guidance at 25.000-25.750 EPS. On average, analysts expect that Chemed Corporation will post 23.55 earnings per share for the current fiscal year.

Chemed Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, September 3rd. Shareholders of record on Monday, August 17th were paid a dividend of $0.70 per share. This is a positive change from Chemed's previous quarterly dividend of $0.60. This represents a $2.80 annualized dividend and a yield of 0.5%. The ex-dividend date of this dividend was Monday, August 17th. Chemed's payout ratio is currently 14.06%.

Insiders Place Their Bets

In other news, CEO Kevin J. Mcnamara sold 2,000 shares of Chemed stock in a transaction that occurred on Monday, September 28th. The shares were sold at an average price of $513.45, for a total value of $1,026,900.00. Following the completion of the transaction, the chief executive officer owned 66,418 shares in the company, valued at approximately $34,102,322.10. The trade was a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Spencer S. Lee sold 1,000 shares of the business's stock in a transaction that occurred on Friday, August 21st. The stock was sold at an average price of $541.04, for a total value of $541,040.00. Following the completion of the transaction, the executive vice president directly owned 13,912 shares in the company, valued at $7,526,948.48. The trade was a 6.71% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 9,190 shares of company stock valued at $4,833,160. 3.33% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of research firms recently weighed in on CHE. Wall Street Zen raised Chemed from a "buy" rating to a "strong-buy" rating in a research report on Saturday, October 10th. Oppenheimer upped their price target on Chemed from $500.00 to $590.00 and gave the company an "outperform" rating in a report on Friday, July 31st. UBS Group assumed coverage on Chemed in a research report on Friday, September 25th. They issued a "buy" rating and a $650.00 price objective for the company. Weiss Ratings raised Chemed from a "hold (c)" rating to a "hold (c+)" rating in a report on Thursday, October 8th. Finally, Royal Bank Of Canada lifted their price objective on Chemed from $436.00 to $548.00 and gave the stock a "sector perform" rating in a report on Thursday, July 30th. Two analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. According to MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $554.60.

Chemed Profile

Chemed Corporation is a diversified services company headquartered in Cincinnati, Ohio. Its operations are organized through two principal businesses: VITAS Healthcare and Roto-Rooter.

VITAS Healthcare provides hospice and palliative care for patients with advanced illnesses. Its services include clinical care, pain and symptom management, emotional and spiritual support, and assistance for patients and their families in homes, hospice residences, hospitals, nursing facilities, and other care settings.

Want to see what other hedge funds are holding CHE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Chemed Corporation (NYSE:CHE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.